SEC EDGARSEP 181 min read$CBLL

Blumberg Scott sold $21K of CBLL

Blumberg Scott (Chief Financial Officer) sold 846 shares of Ceribell, Inc. (CBLL) at $25.00 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Blumberg Scott

Published Sep 18, 2026, 12:40 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 1:03 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The disclosed sale is routine and unlikely to affect Ceribell's valuation.

Market read

Small insider sale with limited trading relevance.

What to watch

Potential upcoming regulatory filings or product news could change relevance.

Relevance 2/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is pre‑arranged.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

CFO Blumberg Scott sold 846 shares of Ceribell for $21,150 via a 10b5‑1 plan.

Expected impact

minimal impact, possible short‑term sell pressure

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for 10b5‑1 plans.

Market effects

Sector

No broader sector impact; Ceribell operates in niche medical devices.

Regional

Limited to US biotech investors.

Global

Negligible

Counterpoint

What could challenge this read

Some traders may view any insider sale as a negative signal despite size.

Key entities

Company
Ceribell, Inc.
Medical device company listed on NASDAQ under CBLL.
Executive
Blumberg Scott
Chief Financial Officer of Ceribell.

Read at source ← All news

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min

AUG 10

$CBLLMedAI 8/10

Ceribell Secures FDA Clearance For Advanced EEG AI Enhancements

Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.

rttnews.com4 min

AUG 3

$CBLLMedAI 8/10

CeriBell stock rises after securing Medicare payment approval

CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.

investing.com3 min

MAY 26

$CBLLMed

Manni Joseph S. sold $25K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

SEC EDGAR2 min